The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with refractory and/or relapsed Richter’s Transformation. The study sponsor is Karyopharm Therapeutics, and the principal investigator at Weill Cornell is Richard Furman M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at email@example.com.
- Men and women age 18 and older.
- Diagnosis of DLBCL in the setting of Richter’s Transformation from CLL.
- Relapsed or refractory after receiving at least 1, and no more than 2, prior chemo-immunotherapy regimens.
- Detailed eligibility reviewed when you contact the study team.
This clinical trial is for men and women with refractory and/or relapsed Richter’s Transformation (RT).
Patients with RT currently have limited treatment options with few options having shown durability. Selinexor has shown tolerability and clinical efficacy in Phase 1 clinical trials in CLL and lymphoma patients. This study will provide information about whether selinexor will be tolerable and effective in subjects with RT.
Subjects will receive selinexor orally, twice weekly (e.g. Monday and Wednesday or Tuesday and Thursday). There is no maximum treatment duration, and subjects will receive selinexor continuously as long as they are responding to therapy and not experiencing unacceptable side effects. After discontinuing treatment, follow-up information will be collected every 3 months throughout the study at clinic visits or through telephone calls.